Published in BMJ on October 31, 2012
Systematic review of model-based cervical screening evaluations. BMC Cancer (2015) 0.98
Expenditure and resource utilisation for cervical screening in Australia. BMC Health Serv Res (2012) 0.86
Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. PLoS One (2016) 0.83
Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res (2016) 0.82
The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol (2014) 0.80
HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions. J Cancer (2016) 0.75
Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. PLoS One (2017) 0.75
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 4.38
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol (1997) 2.71
Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst (2009) 2.17
Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ (2007) 1.97
Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust (2006) 1.92
Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer (2006) 1.87
The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer (2004) 1.38
An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer (2004) 1.21
The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev (2004) 1.18
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales. BJOG (2007) 1.07
HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG (2008) 1.00
Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health (2010) 1.00
Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol (2009) 0.97
Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol (2010) 0.89
Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG (2007) 0.86
Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia. Tumori (2003) 0.79
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Effect of population-based screening on breast cancer mortality. Lancet (2011) 5.06
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
Comparison of screening mammography in the United States and the United kingdom. JAMA (2003) 4.53
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet (2002) 3.58
Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ (2008) 3.32
Research ethics in victimization studies: widening the lens. Violence Against Women (2011) 3.30
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data. BMJ (2009) 2.77
Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer (2008) 2.41
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut (2011) 2.27
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol (2005) 2.26
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut (2011) 2.00
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther (2010) 1.85
Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis (2004) 1.84
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int (2004) 1.68
Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J (2004) 1.68
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis (2011) 1.67
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol (2006) 1.67
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology (2009) 1.64
Road building, land use and climate change: prospects for environmental governance in the Amazon. Philos Trans R Soc Lond B Biol Sci (2008) 1.59
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer (2011) 1.57
Energetic demand of multiple dependents and the evolution of slow human growth. Proc Biol Sci (2006) 1.56
Comparing the performance of mammography screening in the USA and the UK. J Med Screen (2005) 1.52
Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend (2006) 1.51
Option appraisal of population-based colorectal cancer screening programmes in England. Gut (2006) 1.49
Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging (2013) 1.49
Characterization of multiple-antimicrobial-resistant Escherichia coli isolates from diseased chickens and swine in China. J Clin Microbiol (2004) 1.46
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res (2009) 1.40
Rapid sequence induction in children--it's not a matter of time! Or is it? Paediatr Anaesth (2008) 1.38
Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen (2010) 1.38
Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results. Nephrology (Carlton) (2004) 1.38
Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol (2010) 1.36
Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis (2012) 1.35
Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res (2009) 1.35
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb) (2013) 1.34
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis (2003) 1.33
Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol (2013) 1.29
Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer (2011) 1.27
Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res (2013) 1.25
Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet (2013) 1.24
Cervical cancer screening policies and coverage in Europe. Eur J Cancer (2009) 1.23
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine (2011) 1.21
Clinicians' concerns about decision support interventions for patients facing breast cancer surgery options: understanding the challenge of implementing shared decision-making. Health Expect (2010) 1.19
Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol (2004) 1.19
Associations among overeating, overweight, and attention deficit/hyperactivity disorder: a structural equation modelling approach. Eat Behav (2005) 1.19
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer (2011) 1.16
The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Widespread sex differences in gene expression and splicing in the adult human brain. Nat Commun (2013) 1.15
Toward standardizing and reporting colorectal cancer screening indicators on an international level: The International Colorectal Cancer Screening Network. Int J Cancer (2011) 1.15
Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ (2006) 1.14
Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13
Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine (2011) 1.12
False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen (2012) 1.11
The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer (2008) 1.11
Standardization of Gleason grading among 337 European pathologists. Histopathology (2013) 1.09
Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol (2009) 1.08
Comparison of breast and bowel cancer screening uptake patterns in a common cohort of South Asian women in England. BMC Health Serv Res (2010) 1.08
Uptake in cancer screening programmes. Lancet Oncol (2009) 1.08
Id4 is required for the correct timing of neural differentiation. Dev Biol (2005) 1.08
The Jade Goody Effect: whose cervical screening decisions were influenced by her story? J Med Screen (2012) 1.08
Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen (2012) 1.08
Poly peak parser: Method and software for identification of unknown indels using sanger sequencing of polymerase chain reaction products. Dev Dyn (2014) 1.07
Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J (2005) 1.07
Increasing home based dialysis therapies to tackle dialysis burden around the world: a position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology (Carlton) (2011) 1.06
The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry (2003) 1.06
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr (2010) 1.05
Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med (2012) 1.05
Cervical screening in women over the age of 50: results of a population-based multicentre study. BJOG (2004) 1.04
Characterization of the mitochondrial inner membrane protein translocator Tim17 from Trypanosoma brucei. Mol Biochem Parasitol (2008) 1.04
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Adverse impact of a history of violence for women with breast, cervical, endometrial, or ovarian cancer. Obstet Gynecol (2006) 1.02
False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer (2011) 1.02
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Radiologist agreement for mammographic recall by case difficulty and finding type. J Am Coll Radiol (2012) 1.01
Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health (2010) 1.00